Connor, Clark & Lunn Investment Management Ltd. Harmony Biosciences Holdings, Inc. Transaction History
Connor, Clark & Lunn Investment Management Ltd.
- $26 Billion
- Q2 2025
A detailed history of Connor, Clark & Lunn Investment Management Ltd. transactions in Harmony Biosciences Holdings, Inc. stock. As of the latest transaction made, Connor, Clark & Lunn Investment Management Ltd. holds 248,859 shares of HRMY stock, worth $6.48 Million. This represents 0.03% of its overall portfolio holdings.
Number of Shares
248,859
Previous 114,210
117.9%
Holding current value
$6.48 Million
Previous $3.79 Million
107.47%
% of portfolio
0.03%
Previous 0.02%
Shares
4 transactions
Others Institutions Holding HRMY
# of Institutions
289Shares Held
46.3MCall Options Held
316KPut Options Held
69.9K-
Valor Management LLC Chicago, IL6.62MShares$172 Million88.32% of portfolio
-
Black Rock Inc. New York, NY5.84MShares$152 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.11MShares$133 Million0.0% of portfolio
-
State Street Corp Boston, MA1.63MShares$42.4 Million0.0% of portfolio
-
Dimensional Fund Advisors LP Austin, TX1.58MShares$41.2 Million0.01% of portfolio
About Harmony Biosciences Holdings, Inc.
- Ticker HRMY
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,161,400
- Market Cap $1.54B
- Description
- Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony ...